SEC Form 4 · accession 0001209191-15-065009
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Christopher Kemmerer
Officer — VP, Pharma Dev & Manufacturing
Period of report
Aug 7, 2015
Accepted (ET)
Aug 10, 2015 · 7:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2015 | M | 1,000 | $1.22 | A | 11,848 | D | |
| Common Stock | Aug 7, 2015 | S | 1,000 | $12.88 | D | 10,848 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.22 | Aug 7, 2015 | M | 1,000 | D | — | Jan 7, 2019 | Common Stock | 1,000 | 1,710 | D |
Explanation of responses
- F1The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2The option is fully vested.